Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the 44-amino acid sequence of human GHRH with an added trans-3-hexenoic acid group at the N-terminus. This modification provides enhanced stability and potency compared to native GHRH. Tesamorelin is FDA-approved (brand name Egrifta) for the treatment of HIV-associated lipodystrophy, specifically to reduce excess abdominal fat. The peptide stimulates physiological pulsatile GH release without suppressing endogenous GH production. Clinical trials have demonstrated significant reductions in visceral adipose tissue with Tesamorelin treatment.
| Research Status | FDA approved |
|---|---|
| Half-Life | 26-38 minutes |
| Administration | Subcutaneous injection |
| Typical Dosage | 2 mg daily |
| Molecular Weight | 5,135.9 Da |
| Molecular Formula | C221H366N72O67S |
Synthetic GHRH analog with trans-3-hexenoic acid modification, stimulates natural GH release.
All information is presented for Research Use Only (RUO). Not medical advice.